The open-label extension of Vistagen’s PALISADE-4 Phase 3 trial is producing something the randomized portion did not: positive data for fasedienol in the acute treatment of social anxiety disorder. That gap matters because the double-blind, placebo-controlled segment of PALISADE-4 missed its primary endpoint, measured on the Subjective Units of Distress Scale, continuing a pattern set by PALISADE-1 before it. Preliminary results from the extension now give Vistagen a dataset worth examining, though the 8-K filed September 22 discloses only that the data are positive, not what the numbers show.
The clinical relevance of open-label extension findings is always bounded. Without blinding and a concurrent control arm, the data cannot establish efficacy on their own, and the FDA will weigh them accordingly. What they can do is characterize durability, tolerability over repeated use, and real-world dosing patterns in patients who chose to continue, which is a different and narrower question than whether fasedienol beats placebo on a defined anxiety scale. Vistagen describes fasedienol as a 3.2 µg nasal spray, a format designed for on-demand use rather than daily maintenance, setting it apart from the SSRIs and SNRIs that currently carry FDA approval for social anxiety disorder and are taken chronically.
The strategic problem is that two Phase 3 failures on the primary endpoint leave Vistagen arguing from secondary signals and extension data to regulators who expect a clean pivotal win. Open-label extension results, however positive, do not repair a missed primary endpoint; they extend the story rather than replace it. Whether Vistagen uses this data to support a new study design, an NDA filing under a different framework, or a partnership discussion is not stated in the 8-K. The filing attaches the press release as Exhibit 99.1 but the source body available here contains only the 8-K shell, so the specific efficacy numbers remain unpublished at this writing.
The number to watch when the full press release circulates is the responder rate on whatever functional anxiety measure Vistagen used in the extension, because that figure will determine whether the data are compelling enough to warrant a new pivotal design or whether this program has reached the end of its viable path.
Source link: https://www.sec.gov/Archives/edgar/data/1411685/000162828026063046/vtgn-20260922.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
